InvestorsHub Logo

fbg0316

10/01/17 1:22 PM

#36886 RE: mpreorder #36885

You really think the assumption of a 50% market share of all cases of a specified cancer is "conservative"?

ignatiusrielly35

10/01/17 2:45 PM

#36890 RE: mpreorder #36885

The 10% chance of approval assumption is very low. If I recall, Cantor or Jefferies used 80%. And, as you note, your bottom number does not apply any multiplier such as price-to-sales. For KITE it was 10:1. The full value of this company with approval of any significant portion of its platform is several multiples of KITE's $12b.

gajj

10/02/17 1:26 PM

#36956 RE: mpreorder #36885

If you want to try and calculate the value of Advaxis do not apply a multiple to estimated earnings. Instead apply a capitalization rate to earnings. This will provide an estimate of the net present value of earnings in perpetuity. The proper capitalization rate should be an estimate of Advaxis' cost of capital which is an opportunity cost. What rate of return would investors ask for such a high risk stock? Well, its not 5%. If thats all you ant invest in VZ or T. I would suggest 10% or even 20%. A 10% cap rate produces at NPV 10 times the projected annual earnings. 20% produces 5 times.

Recall that the higher the cap rate, the lower the NPV. Also recall that a 20 yr horrizon (the duration of EU patents?)is essentially a
perpetuity for NPV calculations.

When estimating potential earnings you need not only the expected value of returns (probabiity of success x earnings) you also need to consider market penetration when estimating earnings. If your product is cheaper AND more effective than alternatives you can anticipate penetration to be only limited by the ability to supply. Additional capacity will require additional plant which can be readily financed by debt in this circumstance. The cost of debt is much lower today than the cost of capital. Under 5% I would imagine and this leverage reduces the weighted average cost of capital thus magnifying return on equity.

terry hallinan

10/14/17 10:23 AM

#38460 RE: mpreorder #36885

As you can see, this very conservative estimate of the potential of Advaxis...

Conservative indeed, but as absurdly out-of-date as a battle plan for Roman legions in the nuclear age.

Should AMGN buy the remains of ADXS undergoing demolition by primitives, it will not be for constructs but for the LM platform producing and powering a wonderland of vaccine antigens.

Best, Terry

attilathehunt

02/15/18 8:23 AM

#54510 RE: mpreorder #36885

Nice post mp!

So to be even more conservative and discount penetration in half we still are at 4.5B.

In any event, when and if this company is sold we will fetch triple digits (before the .00)